Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 68

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 68
---
,798)(2.91)%248 1.86 %Change in valuation allowance(589)0.93 %2,192 3.55 %2,871 21.58 %Executive compensation2,426 (3.84)%3,171 5.14 %2,188 16.45 %Stock-based compensation9,918 (15.72)%4,070 6.60 %(2,715)(20.41)%Tax credits(5,674)8.99 %(3,327)(5.39)%(3,245)(24.39)%Reserves2,661 (4.22)%389 0.63 %984 7.40 %Goodwill impairment34,281 (54.32)%— — %— — %Non-Taxable or Nondeductible Items:Interest expense— — %— — %(3,477)(26.14)%Contingent consideration(936)1.48 %(719)(1.17)%(3,841)(28.88)%Nondeductible expenses564 (0.89)%975 1.58 %1,164 8.75 %Other131 (0.20)%66 0.10 %(85)(0.64)%Income tax expense (benefit) and effective tax rate$36,454 (57.77)%$19,746 32.00 %$(2,607)(19.60)%

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-37

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. At each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. The Company records a valuation allowance on U.S. capital losses and on foreign net deferred tax balances as it is more-likely-than-not the tax benefits are not realizable.Significant components of the Company’s deferred tax assets and liabilities at December 31, 2024 and 2023 are as follows (in thousands): December